Skip to content

Insider · CIK 0001891113

Ruhi Ahmad Khan

officer

Files at CRBU (Caribou Biosciences, Inc.). First filing Feb 21, 2025, latest Feb 24, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $18k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

CRBU: Caribou Biosciences, Inc.

CRBUOct 9, 2026 · close 0.46

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
10Weak
CRBUsell 410b5-1
Caribou Biosciences, Inc.
$14k
6,938 shares
-6%+192% from low-25% from high
10Weak
CRBUsell 310b5-1
Caribou Biosciences, Inc.
$4,811
3,564 shares
-5%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Feb 20, 2026CRBU
Caribou Biosciences, Inc.
AGrant or award
Common Stock
+45,000$0.00$0111,936Feb 24, 2026
Feb 24, 2026CRBU
Caribou Biosciences, Inc.
SOpen-market sale
Common Stock10b5-1
-6,938$1.96$14k104,998Feb 24, 2026
Feb 20, 2026CRBU
Caribou Biosciences, Inc.
AGrant or award
Option to purchase Common Stockderivative
+202,500$0.00$0202,500Feb 24, 2026
Feb 20, 2025CRBU
Caribou Biosciences, Inc.
AGrant or award
Common Stock
+37,500$0.00$070,500Feb 21, 2025
Feb 21, 2025CRBU
Caribou Biosciences, Inc.
SOpen-market sale
Common Stock10b5-1
-3,564$1.35$4,81166,936Feb 21, 2025
Feb 20, 2025CRBU
Caribou Biosciences, Inc.
AGrant or award
Option to purchase Common Stockderivative
+170,000$0.00$0170,000Feb 21, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.